AnaptysBio

Valuation Analysis

About the Company

AnaptysBio en bref

AnaptysBio (ANAB) is currently trading at 46,26 € with a market capitalization of 1,4 Md €. The 52-week range spans from 9,88 € to 62,74 €; the current price is 26.3% below the yearly high. Year-over-year revenue growth stands at -8.0%.

💰 Dividende

AnaptysBio currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

11 analystes évaluent AnaptysBio (ANAB) au consensus : Achat Fort. L'objectif de cours moyen est de 75,51 €, soit un potentiel de +63.21% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 60,69 € à 121,38 €.

AnaptysBio : la thèse d'investissement en détail

AnaptysBio (ANAB) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 63.21% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue is contracting at -8% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 2175.84% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

The EV/EBITDA multiple of 37.34x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

À surveiller

• The analyst consensus price target implies 63.21% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (37.58%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy AnaptysBio?

Compare top-rated brokers — low fees, trusted providers, fully regulated.